Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.
Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies."
Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented:"I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth."
About Minaris Advanced Therapies:
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.
Minaris Advanced Therapies is a portfolio company of Altaris.
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com
Media Contact:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
9 hours ago
- Korea Herald
KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions
SHANGHAI, July 26, 2025 /PRNewswire/ -- The world premiere of KEENON Robotics' bipedal humanoid service robot, XMAN-F1, takes center stage at the World Artificial Intelligence Conference (WAIC) 2025 in Shanghai from July 26 to 29, where the pioneer in embodied intelligence showcases its latest innovations on the global stage for breakthrough AI advancements. Transforming its showground into an Embodied Service Experience Hub, KEENON immerses visitors in three interactive scenarios—medical station, lounge bar, and performance space—highlighting how embodied AI solution is actively reshaping future lifestyles and industrial ecosystems. At the event, XMAN-F1 emerges as the core interactive demonstration, showcasing human-like mobility and precision in service tasks across diverse scenarios. From preparing popcorn to mixing personalized chilled beverages such as Sprite or Coke with adjustable ice levels, the robot demonstrates remarkable environmental adaptability and task execution. Scheduled stage appearances feature XMAN-F1 autonomously delivering digital presentations and product demos, powered by multimodal interaction and large language model technologies. Its fluid movements and naturalistic gestures establish it as the primary focus of attention, with visitors gathering to witness its engagement live. The demonstration spotlights further multi-robot collaboration in specialized environments. At the medical station, the humanoid XMAN-F1 partners with logistics robot M104 to create a closed-loop smart healthcare solution. The bar area features a highlight collaboration with Johnnie Walker Blue Label—the world's leading premium whisky—where robotic bartenders work alongside delivery robot T10 to craft and serve bespoke beverages. The seamless multi-robot integration not only enhances operational efficiency but signals the dawn of robotic system interoperability, moving far beyond single-task automation. According to IDC's latest report, KEENON leads the commercial service robot sector with 22.7% of global shipments and holds a definitive 40.4% share in food delivery robotics. At WAIC 2025, the company reinforces its market leadership while presenting its ecosystem-based strategy for cross-scenario embodied intelligence solutions. Looking ahead, KEENON will continue driving innovation in embodied intelligence, combining cutting-edge R&D and global partnerships to unlock the full potential of 'Robotics+' applications worldwide.
Korea Herald
12 hours ago
- Korea Herald
CGTN: How China's economy remains vibrant despite U.S. tariff war
BEIJING, July 26, 2025 /PRNewswire/ -- With Chinese Vice Premier He Lifeng to hold economic and trade talks with the United States in Sweden later this month, the strength and resilience of the Chinese economy is in the limelight once again. This round of talks, mutually agreed upon by both nations, is not only a diplomatic engagement but also a testament to China's enduring economic vitality in a complex international environment. Recent statistics underscore the robustness of China's economy. In the first half of 2025, the GDP grew by an impressive 5.3 percent year on year, surpassing market expectations despite global headwinds. This number reflects more than temporary growth; it exhibits the structural resilience and adaptability of an economy that continues to evolve and upgrade. Domestic demand emerged as the cornerstone of growth, contributing 68.8 percent to GDP expansion in this period. Initiatives such as large-scale equipment upgrades and consumer goods trade-in programs have effectively stimulated spending, cushioning China's economy from external shocks. In the first five months of 2025 alone, China's consumer goods trade-in program generated 1.1 trillion yuan ($153.1 billion) in sales, surpassing the figure for entire 2024. Boosted by the program, China's retail sales of consumer goods grew 5 percent year on year in the past six months – 0.4 percentage point faster than the growth recorded in the first quarter. While external uncertainties have introduced some pressure, China's trade diversification and the steady output of high-tech manufacturing and service industries have provided strong support to the economy. Though China's trade with some Western countries declined, its trade with Belt and Road partners, ASEAN countries, the European Union, and African nations saw respective increases of 4.7 percent, 9.6 percent, 3.5 percent, and 14.4 percent in the first half of 2025. This expansion of trade relationships has helped China reduce its reliance on any one market, lessening the impact of some Western economies' protectionist policies. China's resilience reverberates beyond its borders. As a crucial driver of global growth, China's steady economic performance boosts international market confidence and provides a stabilizing influence amid global uncertainties. Through continued focus on quality growth and opening up, China offers the international community a reliable engine for shared prosperity. A recent report from the U.S.-China Business Council indicates that 82 percent of American companies operating in China turned a profit in 2024. Though many cited the uncertainties in China-U.S. relations and tariffs as their main worry, the Chinese market continues to be crucial for them. Trade tensions pose obstacles, yet they have not crippled the resilience in the Chinese economy. The upcoming Beijing-Washington talks in Sweden demonstrate China's willingness to tackle differences via negotiations. While obstacles remain, China's ability to sustain growth, adapt to changing global landscapes, and engage constructively with international partners signals a future of shared opportunities and mutual advancement.
Korea Herald
18 hours ago
- Korea Herald
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the " Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: The hair growth assessment (" HGA") indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013). The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.
